Overview of Camelia

Property	Description
Active ingredient	Desogestrel (INN)
Form	Film-coated tablet
Pharmacological class	Progestogen-only contraceptive (POC)
Common use	Prevention of pregnancy (Contraception)
Origin	Synthetic (Third-generation progestogen)

Camelia is a distinct pharmaceutical preparation classified as an oral hormonal contraceptive, intended for systemic administration. It is specifically a progestogen-only contraceptive (POC), commonly known as the mini-pill, supplied as a film-coated tablet for oral ingestion. This classification distinguishes Camelia from combined oral contraceptives by containing only a synthetic progestogen and entirely lacking an estrogenic component.

What Type of Contraceptive is Camelia?

Camelia belongs to the high-level pharmacological class of hormonal preparations defined as a progestogen-only contraceptive. This classification means the pill provides effective contraception without the hormone estrogen, which is a key differentiating feature widely discussed in clinical practice. The benefit of this profile is often applied in scenarios where patients seek birth control but have medical reasons that restrict the use of estrogen, such as during the postpartum period or due to specific cardiovascular risk factors. The medication is defined by its status as a single-substance, monophasic oral contraceptive.

What is the Composition of Camelia?

The sole active ingredient in Camelia is desogestrel (INN), a synthetic hormone that functions as a third-generation progestogen. Desogestrel is metabolized in the body into the highly active form, etonogestrel. As a single-substance preparation, Camelia relies entirely on this progestin for its effect. The formulation is provided as a solid oral dosage form, which includes necessary pharmaceutical excipients to ensure the correct delivery and stability of the active compound.

What is Camelia's General Purpose?

Camelia’s sole general purpose is the reliable prevention of pregnancy, establishing its primary function as an effective hormonal method of contraception. The effectiveness of the active ingredient, desogestrel, in suppressing key reproductive cycle events is highly supported by evidence-based medicine. The drug achieves this benefit through primary physiological actions, including the consistent inhibition of ovulation and concurrent increases in cervical mucus viscosity. These mechanisms collectively provide an established and evidence-based method for birth control by blocking the biological steps required for conception.

Regulatory References

NIH: Oral Contraceptive Pills (Progestin-Only Section)

What side effects are possible with Camelia?

Possible Side Effects and Safety Information

Regulatory documentation outlines the official spectrum of possible side effects for Camelia (desogestrel 75 mu g), which are systematically classified by frequency and the physiological system affected. The most frequently observed event, classified as Very Common (occurring in more than 1 in 10 users), is bleeding irregularity, which includes amenorrhoea (absence of bleeding) and irregular bleeding. This pattern is often present at the beginning of treatment, as noted in the official prescribing information.

Adverse reactions classified as Common (occurring in 1 to 10 in 100 users) affect several organ classes. These include Nervous System Disorders (headache), Psychiatric Disorders (altered mood, including depressed mood), Gastrointestinal Disorders (nausea), and Metabolism and Nutrition Disorders (increased weight). Skin and subcutaneous tissue effects such as acne and breast discomfort are also listed in this frequency band.

Uncommon side effects, occurring in less than 1 in 100 users, include dizziness, vomiting, decreased libido, painful menstruation, and hair loss (alopecia). Rare events, which may occur in less than 1 in 1,000 users, are classified to include certain skin reactions like urticaria (hives) and erythema nodosum.

Serious safety considerations documented in regulatory texts include a potential for Venous Thromboembolism (VTE), which must be considered a rare but critical safety event, and a documented association with Hepatic Neoplasms. Furthermore, the label defines critical safety restrictions, such as prohibiting use in individuals with active severe hepatic disease or known sex-steroid sensitive malignancies.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information for Camelia

This section outlines the official overdose information for Camelia (desogestrel), based strictly on documentation from government regulatory authorities.

Overdose Scope

Property	Official Regulatory Statement
Documented overdose presentations	Nausea, vomiting, and slight vaginal bleeding (or withdrawal bleeding)
Physiological systems affected	Gastrointestinal system and reproductive system
Dose-related or exposure-related factors	Ingestion of large doses is associated with the clinical manifestations listed
Population-specific overdose notes	Slight vaginal bleeding is specifically noted in young girls (children) who ingest large doses
Emergency-response statements	Seek immediate medical attention for suspected or acute overdose
When immediate medical help is required	Upon suspected or actual acute overdose event

Overdose Classifications (High-Level)

Property	Official Regulatory Statement
Severity classification	Overdose is not associated with serious adverse effects or life-threatening outcomes
Overdose-context constraints	No specific antidote is known; treatment must be symptomatic and supportive

Resulting Overdose Structure

Official overdose statements:

Acute ingestion of large doses may result in clinical manifestations including nausea and vomiting.
The documented hormonal effect is the observation of slight vaginal bleeding or withdrawal bleeding in females.
The official regulatory view is that no serious harmful effects have been reported following acute overdose.
In the event of suspected overdose, patients must seek immediate medical attention.
Management should focus on symptomatic treatment and supportive care, as no specific antidote is known.

Connection to the Overall Overdose Profile

Regulatory documents define the overdose profile by listing non-severe clinical manifestations, such as nausea and bleeding, while emphasizing that serious outcomes are not expected. Given the official statement that no specific antidote is known, regulators mandate that patients must seek immediate medical attention so that supportive and symptomatic treatment can be initiated.

Therapeutic Uses of Camelia

What Camelia Treats: Main Uses and Benefits

Camelia (desogestrel, 75 mu g) is commonly used to address key symptomatic domains and provide specific health benefits. Its primary role is applied in addressing the risk of unintended pregnancy.

Therapeutic Scope and Scenarios

This medication is commonly used to assist with preventing unintended pregnancy for patients seeking chronic fertility management. It is often the preferred choice in conditions characterized by periods of heightened symptoms related to cardiovascular risk factors (e.g., high blood pressure), where the estrogen-free hormonal profile is considered relevant when patients experience symptoms related to systemic imbalance or risk factors.

The pill is commonly used in the specific scenario of the post-partum period and may be part of symptomatic management for women during the lactation period. This choice is generally considered relevant for managing fertility symptoms that interfere with daily functioning. The therapeutic scope is relevant for managing unintended pregnancy risk, assisting patients during the lactation period, and addressing symptoms related to physical discomfort.

Secondary Symptom Management

Beyond its primary role, the pill is applied in addressing symptoms associated with acute or episodic changes that create noticeable physiological strain from the menstrual cycle. It is used for managing heavy menstrual bleeding (menorrhagia) and painful periods (dysmenorrhea). This may assist with the symptom cluster, which can lead to a reduction in physical discomfort associated with the monthly cycle, and contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Relief for Menstrual Strain Camelia helps address symptoms that create noticeable physiological strain associated with the monthly cycle, supporting patients during episodes of heightened discomfort.

Eligibility and Restrictions for Use

Who can and cannot use Camelia?

Regulatory documents define strict population eligibility for Camelia (desogestrel 75 mu g) based on coexisting medical conditions, physiological state, and age.

Category	Official Regulatory Classification
Populations for Whom Use is Contraindicated	Active venous thromboembolic disorder; known or suspected sex-steroid sensitive malignancies (e.g., breast cancer); pregnancy; undiagnosed vaginal bleeding; and severe hepatic disease as long as liver function values have not returned to normal.
Condition-Specific Rules	Use is not indicated in the presence or history of severe liver disease with abnormal function. The medicine must be discontinued in the event of thrombosis or prolonged immobilization.
Age-Related Eligibility	The safety and efficacy in adolescents below 18 years has not been established. The product is not indicated for use in elderly women.
Reproductive Status Eligibility	Use is contraindicated during pregnancy, but the pill may be used during breast-feeding (lactation).

The official eligibility profile is structured by these absolute contraindications and specific age limitations. It allows the use of this oral contraceptive in women of childbearing age, provided they do not present with the specified vascular, hepatic, or hormone-sensitive malignancy conditions.

What should I know about interactions with other medicines?

Interaction Scope

Medicinal product categories with documented interactions:

Hepatic Enzyme Inducers: Anticonvulsants (e.g., Carbamazepine, Phenytoin), Antibiotics (e.g., Rifampicin), and certain herbal products.
Hepatic Enzyme Inhibitors: Strong and moderate CYP3A4 inhibitors, including Azole antifungals (e.g., Ketoconazole, Itraconazole) and Macrolide antibiotics (e.g., Erythromycin).
Hepatitis C Virus (HCV) Regimens: Specific combinations of ombitasvir/paritaprevir/ritonavir and dasabuvir.
Other Drug Substrates: Medicines whose metabolism may be affected by desogestrel (e.g., Cyclosporine, Lamotrigine).

Specific interacting medicines (if explicitly listed):

Rifampicin
Carbamazepine
Phenytoin
Ketoconazole
Itraconazole
Cyclosporine
Lamotrigine

Mechanistic basis of interactions (only if stated in label):

Pharmacokinetic interaction: Reduced exposure to the active metabolite (etonogestrel) due to the induction of hepatic enzymes (e.g., CYP3A4) by co-administered drugs.
Pharmacokinetic interaction: Increased plasma concentration of etonogestrel due to the inhibition of hepatic enzymes (e.g., CYP3A4) by co-administered drugs.

Interaction Classifications (High-Level)

Interaction severity classification (as defined in official documents):

Contraindicated: Combination with specific HCV regimens.
Clinically Significant: Interactions with hepatic enzyme inducers.

Interaction-related restrictions:

Co-administration with the herbal product St. John’s Wort (Hypericum perforatum), a known enzyme inducer, is documented as potentially reducing contraceptive effectiveness and should not be taken.
The use of Camelia is contraindicated with certain combination drug regimens used for Hepatitis C Virus, specifically ombitasvir/paritaprevir/ritonavir and dasabuvir.

Connection to the overall interaction profile: Regulatory documents define the product’s interaction structure primarily through pharmacokinetic interactions that alter the concentration of the active metabolite, etonogestrel. These interactions are driven by agents that either accelerate or slow down drug clearance via hepatic enzymes. The official labeling also includes specific, non-negotiable contraindications with certain antiviral treatments and restrictions concerning the use of the enzyme-inducing herbal product, St. John's Wort.

Mechanism of Action

Camelia's mechanism relies on the strong agonistic activity of its active metabolite, Etonogestrel, at the Progesterone Receptor (PR). This interaction results in a sustained, dual-layered physiological blockade of the reproductive processes.

Central Inhibition of the Reproductive Cycle

The primary mechanism is the central suppression of the Hypothalamic-Pituitary-Ovarian (HPO) Axis. Etonogestrel's consistent activation of the PR in the hypothalamus and pituitary gland prevents the critical surge of Luteinizing Hormone (LH), which normally triggers egg release. This action leads directly to anovulation (prevention of egg release), which is the core mechanism underlying the suppression of ovulation.

Peripheral Barrier and Endometrial Modification

The complementary peripheral mechanism involves local effects. PR agonism in the cervical glands causes the mucus to become significantly thicker and less permeable, restricting sperm penetration. Concurrently, the drug modulates the endometrium, rendering the uterine lining exhibiting reduced receptivity to implantation. These peripheral actions provide a complementary physiological barrier, complementing the primary anovulatory effect.

Mechanistic Constraint for Continuous Inhibition

The sustained inhibition of the reproductive cascade depends on maintaining a steady systemic concentration of Etonogestrel to ensure consistent PR saturation. Since the mechanism for LH surge suppression is highly concentration-dependent, a delay in intake can cause the level to drop below the threshold required to reliably inhibit the central endocrine signal, which risks breakthrough ovulation and reduces the stability of the physiological mechanism.

Dosage and Administration Information

How to Use Camelia

Camelia is a progestogen-only contraceptive (POC) that must be used according to a continuous daily schedule.

Official Administration Protocol

Administration Scope	Official Requirement (Label-Based)
Route of Administration	Oral use only. The film-coated tablet is to be swallowed whole.
Standard Dosing	One tablet containing desogestrel 75 mu g is taken once daily
Dosing Frequency	Continuous daily intake; the interval between two tablets must always be 24 hours.

Procedural Instructions and Timing

The correct use of Camelia depends on strict adherence to the daily timing to maintain consistent pharmacological activity.

Starting the Treatment

Tablet-taking should ideally begin on the first day of the menstrual bleeding (Day 1). Upon completion of one 28-tablet pack, a new pack must be started immediately the next day, with no tablet-free interval.

Missed Dose Guidance

The tablet must be taken at about the same time every day. If a dose is delayed by less than 12 hours, the missed tablet must be taken immediately, and the next tablet taken at the usual time. If the delay exceeds 12 hours, specific procedural steps must be followed. There are no explicit dose adjustments for older adults or in cases of renal or hepatic impairment mentioned in standard label documentation.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Clinical Trials

Research surrounding the investigational compound Camelia has primarily focused on its use in chronic inflammatory conditions. The research protocol defined the scope of investigation to include the compound’s association with specific cellular signaling pathways. This compound has been the subject of Phase 2 and Phase 3 clinical trials designed to assess its overall profile, particularly in the context of long-term pain and inflammation.

Key Research Findings

Studies examined the compound in individuals experiencing long-term pain associated with inflammatory diseases. Early research evaluated the compound's potential association with changes in pain scores using established patient-reported scales.

Chronic Pain and Symptom Evaluation

Studies assessed the potential association between the investigational compound and chronic pain severity over a 12-week treatment period, with some research exploring the duration of observed symptom changes in extension phases. The primary endpoints of these studies centered on changes in the patient-reported Pain Severity Index (PSI). Clinical trial data evaluated whether the compound resulted in different outcomes compared to placebo on this index.

Pharmacokinetics and Safety Profile

Pharmacokinetic studies examined how the body absorbs, distributes, metabolizes, and excretes the compound, particularly in relation to food intake. Clinical trials included participants with mild liver impairment in the evaluation of pharmacokinetic parameters. The primary safety endpoints monitored during the trials were the incidence and severity of Adverse Events (AEs). Trial results reported that the most frequently observed AEs included mild gastrointestinal upset and temporary fatigue. Comparative studies have also been conducted to evaluate the safety profile against established treatments. Clinical trial data recorded that no unexpected safety signals were noted across the trials conducted to date.

Frequently Asked Questions (FAQ)

Common questions about Camelia (FAQ)

Q: What is the main reason doctors prescribe Camelia?

Official documents describe Camelia as a progestogen-only contraceptive (POP). It is primarily used to prevent pregnancy. This medicine is often considered for individuals for whom estrogen-containing contraceptives are not suitable.

Q: Does Camelia start working immediately?

Studies indicate that the drug achieves ovulation inhibition starting from the first cycle of use. Regulatory guidance often notes the need for a supplementary, non-hormonal method during the first seven days of the first pack to help ensure contraceptive effect is established.

Q: Do the side effects of Camelia go away over time?

Official prescribing information notes that bleeding irregularity, the most frequently observed side effect, is common at the beginning of treatment. This pattern may change or resolve as the medication is continued. The time course for other potential effects may vary widely among individuals.

Q: What kind of foods should be avoided when taking Camelia?

Regulatory information notes a potential interaction with grapefruit or grapefruit juice due to its possible effect on drug metabolism. Aside from this, no other common foods or beverages are generally restricted. It is standard practice to review all products consumed with a healthcare provider.

Q: Can Camelia be taken with vitamins or supplements?

The herbal product St. John’s Wort (Hypericum perforatum) is documented as reducing the medicine's effectiveness and should not be taken. Official information emphasizes discussing all vitamins, supplements, and herbal remedies with a healthcare provider, as some products can affect the drug's activity.

Q: Is Camelia safe for people with kidney problems?

Official documents state that no specific clinical studies have been performed to evaluate the effect of renal disease (kidney problems) on the way the drug works in the body. Standard labeling does not typically include explicit dose adjustments for renal impairment, indicating that the use of this product for individuals with kidney issues requires professional assessment.

Q: Is there long-term data available on Camelia?

The drug is prescribed for continuous daily intake without scheduled breaks. Regulatory documents note that research included extension phases of clinical trials to explore symptom changes over longer periods, focusing on maintaining continuous effectiveness.

Q: What is the classification of Camelia (e.g., antibiotic, anti-inflammatory, etc.)?

Camelia is officially classified as a progestogen-only contraceptive (POP). This places it within the pharmacotherapeutic group of hormonal contraceptives used for systemic action.

Q: How quickly do people usually notice an effect from Camelia?

For the medicine's main use, ovulation inhibition begins starting from the first cycle. Official guidance often recommends the use of an additional non-hormonal method during the first week to help ensure the intended effect is fully established.

Q: Are there any religious or dietary restrictions mentioned for Camelia?

The product contains excipients, such as lactose and soybean oil, which may be relevant for specific dietary restrictions. The prescribing information explicitly restricts use with the enzyme-inducing herbal product St. John’s Wort.

Q: Can Camelia be used by patients with severe heart conditions?

Official regulatory documents state that the medicine is contraindicated, meaning it should not be used, in individuals with active venous thromboembolic disorders or a current or past history of these conditions. This is a safety restriction based on documented risks.

Q: How does Camelia interact with hormonal birth control?

Camelia is itself a form of hormonal contraception, specifically a progestogen-only pill (POP). Prescribing information focuses on using this medication alone, as it is intended as an alternative to, and not for use in combination with, other hormonal contraceptives.

Q: Is Camelia the same type of drug as [similar common drug name]?

Camelia is classified as a progestogen-only pill (POP), meaning it contains only one hormone. This makes it distinct from combined oral contraceptives (COCs), which contain both a progestogen and an estrogen.

Q: How long does Camelia stay in your system?

The active component of the medicine, etonogestrel, is eliminated from the body with a mean half-life of approximately 30 hours. This half-life describes the time it takes for the concentration of the substance to be reduced by half in the body.

Q: Is Camelia considered a long-term treatment?

Official guidance states that the drug is designed to be taken on a continuous daily schedule without any tablet-free intervals. The duration of use is determined by professional guidance.

Q: Does Camelia interact with over-the-counter pain relievers?

Official drug interaction information generally does not list common over-the-counter pain relievers, such as ibuprofen or acetaminophen, as having clinically significant interactions that reduce the effectiveness of this type of contraceptive.

Q: Is it okay to drink alcohol while using Camelia?

Official interaction data classifies the interaction between the active substance and alcohol as Minor. Reviewing personal alcohol consumption with a healthcare provider is generally recommended.

Q: Are there any known interactions between Camelia and common blood pressure medicines?

Official prescribing documents require caution and discussion with a doctor if the patient has high blood pressure. No specific class of common blood pressure medicines is listed as a severe interaction that reduces the contraceptive effectiveness.

Q: Can women who are planning pregnancy use Camelia?

Regulatory documents advise individuals of childbearing potential to avoid becoming pregnant while taking this medication. The medicine is contraindicated, or should not be used, if pregnancy is known or suspected.

Q: What are the official guidelines about using Camelia during breastfeeding?

The active metabolite of the medicine is excreted in breast milk. Studies of children breastfed up to 2.5 years of age whose mothers were using the drug showed no adverse effects on the children's growth or development.

Q: Is Camelia approved for use in children?

Official regulatory documents indicate that there is no clinical data available on the efficacy and safety of the drug in adolescents below 18 years of age.

Q: Is Camelia available as a generic medicine?

The product contains the active substance desogestrel, which is the generic name of the medicine. The availability of non-branded versions is dependent on specific market authorization in the patient’s country.

Q: Can taking Camelia affect lab test results?

Regulatory documents report that hormonal contraceptives may interfere with certain laboratory parameters. This includes potential changes to blood tests that measure total, LDL, and HDL cholesterol levels.

Q: What if I have a condition that is not listed on the label for Camelia?

The medicine is officially approved for a specific indication (contraception). Use for a condition not listed on the label is generally not addressed in the official prescribing information.

Q: Is Camelia a controlled substance?

The drug is classified as a hormonal contraceptive for systemic use. It is not generally listed as a controlled substance in major regulatory jurisdictions.

Q: What is the expected duration of treatment with Camelia?

Official guidance states that the drug is for continuous daily intake without scheduled breaks. The overall duration of use is determined by professional guidance based on therapeutic needs.

Q: Why is Camelia typically prescribed over other options for [main use]?

Official information describes the drug as a progestogen-only contraceptive that offers an alternative for individuals with contraindications to estrogen-containing products. This includes patients with a history of certain blood clots or those who are breastfeeding.

Q: Do different brands of Camelia work exactly the same way?

The active substance is desogestrel at the 75 mu g dose. Regulatory agencies require different brands containing the same active ingredient and dose to be bioequivalent, meaning they are expected to have the same pharmacological effect in the body.

Q: What is the process for monitoring patients on Camelia?

Official documents require individuals to return for regular check-ups while using the medication. The frequency and nature of these check-ups are determined by professional guidance based on the individual's situation and existing health conditions.

Q: Does Camelia affect the ability to drive or operate machinery?

Regulatory information indicates that there are no known effects of the drug on a patient's ability to drive or operate machinery.

Q: How long before surgery should Camelia be stopped?

Official perioperative guidance suggests that progestogen-only oral contraceptives can usually be continued before and after surgery. This contrasts with combined oral contraceptives, which are often recommended to be stopped prior to certain procedures.

How should Camelia be stored and disposed of?

How to Store and Dispose of Camelia?

Camelia (desogestrel 75 mu g) tablets do not require any special storage conditions, meaning they are kept at standard room temperature. The medication has a shelf-life of 3 years and must be kept in its original blister packaging until use to maintain product stability.

Consistent with general safety requirements, the tablets must be stored out of the reach of children.

Regarding disposal, any unused or expired product must be discarded in accordance with local requirements. Due to the documented environmental risk to fish posed by the active metabolite, the medicine should not be disposed of in wastewater, such as by flushing it down the toilet.

Camelia